- Home
- XRTX vs TIVC Comparison
XRTX vs TIVC Comparison
Compare XRTX & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRTX | TIVC |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XRTX | TIVC |
|---|---|---|
| Price | $2.00 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 133.1K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.75 |
| 52 Week High | $3.60 | $5.60 |
Technical Indicators
Market Signals| Indicator | XRTX | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 41.83 | 69.31 |
| Support Level | $0.41 | $0.79 |
| Resistance Level | $3.03 | $2.70 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 4.49 | 100.00 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.